Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Jason B. White"'
Autor:
Reid T. Powell, Amanda L. Rinkenbaugh, Lei Guo, Shirong Cai, Jiansu Shao, Xinhui Zhou, Xiaomei Zhang, Sabrina Jeter-Jones, Chunxiao Fu, Yuan Qi, Faiza Baameur Hancock, Jason B. White, Clifford Stephan, Peter J. Davies, Stacy Moulder, W. Fraser Symmans, Jeffrey T. Chang, Helen Piwnica-Worms
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-12 (2024)
Abstract Triple negative breast cancer (TNBC) accounts for 15–20% of breast cancer cases in the United States. Systemic neoadjuvant chemotherapy (NACT), with or without immunotherapy, is the current standard of care for patients with early-stage TN
Externí odkaz:
https://doaj.org/article/388c05310d9142b793c6b22617755d55
Autor:
Zijian Zhou, Beatriz E. Adrada, Rosalind P. Candelaria, Nabil A. Elshafeey, Medine Boge, Rania M. Mohamed, Sanaz Pashapoor, Jia Sun, Zhan Xu, Bikash Panthi, Jong Bum Son, Mary S. Guirguis, Miral M. Patel, Gary J. Whitman, Tanya W. Moseley, Marion E. Scoggins, Jason B. White, Jennifer K. Litton, Vicente Valero, Kelly K. Hunt, Debu Tripathy, Wei Yang, Peng Wei, Clinton Yam, Mark D. Pagel, Gaiane M. Rauch, Jingfei Ma
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-10 (2023)
Abstract Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer. Neoadjuvant systemic therapy (NAST) followed by surgery are currently standard of care for TNBC with 50-60% of patients achieving pathologic complete response (p
Externí odkaz:
https://doaj.org/article/9d1afc4d0a46451ea11ba6d0e3bea0a2
Autor:
Gloria V. Echeverria, Shirong Cai, Yizheng Tu, Jiansu Shao, Emily Powell, Abena B. Redwood, Yan Jiang, Aaron McCoy, Amanda L. Rinkenbaugh, Rosanna Lau, Alexander J. Trevarton, Chunxiao Fu, Rebekah Gould, Elizabeth E. Ravenberg, Lei Huo, Rosalind Candelaria, Lumarie Santiago, Beatriz E. Adrada, Deanna L. Lane, Gaiane M. Rauch, Wei T. Yang, Jason B. White, Jeffrey T. Chang, Stacy L. Moulder, W. Fraser Symmans, Susan G. Hilsenbeck, Helen Piwnica-Worms
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-9 (2023)
Abstract Patient-derived xenograft (PDX) models of breast cancer are an effective discovery platform and tool for preclinical pharmacologic testing and biomarker identification. We established orthotopic PDX models of triple negative breast cancer (T
Externí odkaz:
https://doaj.org/article/1aeaec90b47b427c8b0d10b0dad9ddf6
Autor:
Xuan Liu, Zhongqi Ge, Fei Yang, Alejandro Contreras, Sanghoon Lee, Jason B. White, Yiling Lu, Marilyne Labrie, Banu K. Arun, Stacy L. Moulder, Gordon B. Mills, Helen Piwnica-Worms, Jennifer K. Litton, Jeffrey T. Chang
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-13 (2022)
Abstract Germline mutations in BRCA1 or BRCA2 exist in ~2–7% of breast cancer patients, which has led to the approval of PARP inhibitors in the advanced setting. We have previously reported a phase II neoadjuvant trial of single agent talazoparib f
Externí odkaz:
https://doaj.org/article/c1596f6b174a47a78043a40e8d62cdcd